This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2018
  • /
  • 11
  • /
  • FDA Advisory Committees recommended approval of ab...
Drug news

FDA Advisory Committees recommended approval of abuse deterrent reformulation of Roxicodone by the nasal route to manage severe pain.- SpecGx / Mallinckrodt.

Read time: 1 mins
Last updated:16th Nov 2018
Published:16th Nov 2018
Source: Pharmawand

SpecGx LLC , a subsidiary of Mallinckrodt plc, that operates its Specialty Generics business, announced that, in a joint meeting, the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 10 to 7 to approve the SpecGx investigative abuse-deterrent formulation of immediate-release, single-entity oxycodone tablets for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Additionally, the Committees voted 12 to 5 that the drug should be labeled as an abuse-deterrent product by the nasal route of abuse. The Committees also voted 10 to 7 that the drug should not be labeled as an abuse-deterrent product by the intravenous route of abuse.

SpecGx is advancing this reformulation of Roxicodone (oxycodone hydrochloride tablets USP) with properties designed to deter intravenous and intranasal abuse under the company's 505(b)2 new drug application MNK-812.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.